|
Sun Pharmaceutical Industries Ltd up for third consecutive session> |
|
Sun Pharmaceutical Q2 PAT declines 36% YoY> |
|
Sun Pharma receives USFDA approval for ILUMYA® (tildrakizumab-asmn)> |
|
Sun Pharmaceutical Industries consolidated net profit declines 36.22% in the September 2026 quarter> |
|
Sun Pharma raises Rs 7,816 cr via NCDs> |
|
Sun Pharma announces elevation of UNLOXCYT to NCCN®) Category 2A recommendation> |
|
Volumes soar at L&T Technology Services Ltd counter> |
|
Sun Pharmaceuticals Industries announces board meeting date> |
|
Sun Pharma receives ratings action from ICRA> |
|
Sun Pharma receives affirmation in credit ratings from CRISIL> |